ProfileGDS5678 / 1442775_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 64% 64% 63% 64% 66% 71% 64% 63% 63% 64% 64% 67% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0759467
GSM967853U87-EV human glioblastoma xenograft - Control 23.8360664
GSM967854U87-EV human glioblastoma xenograft - Control 33.8465764
GSM967855U87-EV human glioblastoma xenograft - Control 43.7442363
GSM967856U87-EV human glioblastoma xenograft - Control 53.7768964
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0201666
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4164271
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8469564
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7951463
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.792363
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8561164
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7937664
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0409567
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8583164